Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 5
2020 3
2021 4
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
Miyata H, Hirohashi Y, Yamada S, Yanagawa J, Murai A, Hashimoto S, Tokita S, Hori K, Abe T, Kubo T, Tsukahara T, Kanaseki T, Shinohara N, Torigoe T. Miyata H, et al. Cancer Immunol Immunother. 2022 Apr;71(4):795-806. doi: 10.1007/s00262-021-03025-z. Epub 2021 Aug 18. Cancer Immunol Immunother. 2022. PMID: 34405274 Free PMC article.
Tumor-infiltrating CD8+ T cells recognize a heterogeneously expressed functional neoantigen in clear cell renal cell carcinoma.
Matsuki M, Hirohashi Y, Nakatsugawa M, Murai A, Kubo T, Hashimoto S, Tokita S, Murata K, Kanaseki T, Tsukahara T, Nishida S, Tanaka T, Kitamura H, Masumori N, Torigoe T. Matsuki M, et al. Cancer Immunol Immunother. 2022 Apr;71(4):905-918. doi: 10.1007/s00262-021-03048-6. Epub 2021 Sep 7. Cancer Immunol Immunother. 2022. PMID: 34491407 Free PMC article.
Less correlation between mismatch repair proteins deficiency and decreased expression of HLA class I molecules in endometrial carcinoma: a different propensity from colorectal cancer.
Mariya T, Kubo T, Hirohashi Y, Yanagawa J, Tabuchi Y, Matsuo K, Furumura K, Morita R, Nakatsugawa M, Kanaseki T, Tsukahara T, Hasegawa T, Saito T, Torigoe T. Mariya T, et al. Med Mol Morphol. 2021 Mar;54(1):14-22. doi: 10.1007/s00795-020-00254-6. Epub 2020 May 14. Med Mol Morphol. 2021. PMID: 32410009
Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: Analysis of an autopsy series.
Kubo T, Tsurita G, Hirohashi Y, Yasui H, Ota Y, Watanabe K, Murai A, Matsuo K, Asanuma H, Shima H, Wada S, Nakatsugawa M, Kanaseki T, Tsukahara T, Mizuguchi T, Hirata K, Takemasa I, Imai K, Sato N, Torigoe T. Kubo T, et al. Cancer Sci. 2019 Aug;110(8):2386-2395. doi: 10.1111/cas.14099. Epub 2019 Jul 11. Cancer Sci. 2019. PMID: 31206934 Free PMC article. Clinical Trial.
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma.
Shima H, Tsurita G, Wada S, Hirohashi Y, Yasui H, Hayashi H, Miyakoshi T, Watanabe K, Murai A, Asanuma H, Tokita S, Kubo T, Nakatsugawa M, Kanaseki T, Tsukahara T, Nakae Y, Sugita O, Ito YM, Ota Y, Kimura Y, Kutomi G, Hirata K, Mizuguchi T, Imai K, Takemasa I, Sato N, Torigoe T. Shima H, et al. Cancer Sci. 2019 Aug;110(8):2378-2385. doi: 10.1111/cas.14106. Epub 2019 Jul 23. Cancer Sci. 2019. PMID: 31218770 Free PMC article. Clinical Trial.
11 results